2024
Characterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States
Jacobs J, Booth G, Moise K, Adkins B, Bakhtary S, Fasano R, Goel R, Hinton H, Laghari S, Stephens L, Tormey C, Crowe E, Bloch E, Abels E. Characterization of blood bank and transfusion medicine practices for pregnant individuals with fetuses at risk of hemolytic disease in the United States. Transfusion 2024 PMID: 39248602, DOI: 10.1111/trf.18011.Peer-Reviewed Original ResearchRisk of HDFNAntigen testAntibody titersHemolytic diseaseRed blood cellsCell-free fetal DNA testingRisk of hemolytic diseaseCell-free fetal DNAMaternal antibody titersPregnant individualsFetal DNA testingBlood banksTransfusion medicine practiceFetal DNALaboratory testing practicesThird trimesterAntigen statusTransfusion medicine serviceAntigen resultsMedicine serviceFetusesHDFNCritical titerResponse rateDNA testing
2023
Assessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice?
Abels E, Adkins B, Cedeno K, Booth G, Allen E, Stephens L, Woo J, Tormey C, Jacobs J. Assessing Recommendations for Determining Fetal Risk in Alloimmunized Pregnancies in the United States: Is It Time to Update a Decades-Old Practice? Transfusion Medicine Reviews 2023, 38: 150810. PMID: 38194730, DOI: 10.1016/j.tmrv.2023.150810.Peer-Reviewed Original ResearchAntigen testingEvidence-based recommendationsFetal risksAlloimmunized pregnanciesPoor outcomeHemolytic diseasePractice guidelinesDecades-old practiceNarrative reviewTransfusion medicineUnnecessary riskRecent evidencePregnancyUnited StatesFetusesRiskCurrent United StatesValuable alternativeTesting algorithmObstetriciansCurrent landscapeDiseaseRecommendations